•
Jun 30, 2022

Tscan Therapeutics Q2 2022 Earnings Report

Reported financial results for the second quarter and provided business updates.

Key Takeaways

TScan Therapeutics reported a revenue of $4.1 million for the second quarter, primarily driven by research activities related to the collaboration agreement with Novartis. The company's cash and cash equivalents totaled $125.6 million, sufficient to fund operations into 2024. Net loss for the quarter was $15.1 million.

Phase 1 umbrella trial for hematologic malignancies is open for enrollment.

Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs.

TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings are anticipated by year-end 2022.

Debora Barton, M.D., was appointed as Chief Medical Officer.

Total Revenue
$4.06M
Previous year: $2.85M
+42.4%
EPS
-$0.63
Previous year: -$7.69
-91.8%
Gross Profit
$2.85M
Previous year: -$7.95M
-135.8%
Cash and Equivalents
$126M
Previous year: $106M
+18.3%
Free Cash Flow
-$15.3M
Previous year: -$14.6M
+4.4%
Total Assets
$152M
Previous year: $130M
+17.2%

Tscan Therapeutics

Tscan Therapeutics

Tscan Therapeutics Revenue by Segment

Forward Guidance

TScan Therapeutics anticipates several near-term catalysts, including providing an update on the Phase 1 umbrella trial for TSC-100 and TSC-101 by the end of 2022, progressing IND-enabling studies for solid tumor programs, and submitting IND applications for two TCRs by the end of 2022.

Positive Outlook

  • Progressing IND-enabling studies for solid tumor programs.
  • Submitting IND applications for two TCRs by the end of 2022, including TSC-200-A2 for HPV and TSC-204-C7 for MAGE-A1.
  • Filing additional INDs for solid tumor programs by the end of 2023.
  • Releasing initial clinical data for TCRs in the solid tumor series by the end of 2023.
  • Existing cash and cash equivalents are expected to fund operating expenses and capital expenditure requirements into 2024.

Challenges Ahead

  • Up to 40% of patients who receive HCT with RIC relapse within two years, at which point there are limited treatment options and poor prognosis.
  • The company reported a net loss of $15.1 million for the second quarter ended June 30, 2022.
  • Research and development expenses increased by $3.7 million compared to the same quarter in the previous year.
  • General and administrative expenses increased by $2.1 million compared to the same quarter in the previous year.
  • The company's future success depends on the successful development and commercialization of its TCR-T therapy candidates, which are subject to numerous risks and uncertainties.